<DOC>
	<DOCNO>NCT00003772</DOCNO>
	<brief_summary>RATIONALE : Quality-of-life assessment patient undergoing cancer treatment may help determine intermediate- long-term effect treatment . PURPOSE : This clinical trial study quality life patient ovarian cancer .</brief_summary>
	<brief_title>Quality-of-Life Assessment Patients With Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate scale structure reliability ovarian cancer specific questionnaire module ( EORTC QLQ-OV28 ) design use conjunction standard nonspecific questionnaire ( EORTC QLQ-C30 ) patient ovarian epithelial cancer . II . Evaluate psychometric property revise scale ( physical role functioning ; global health status/QL ) EORTC QLQ-C30 among ovarian cancer patient . III . Evaluate evidence validity EORTC QLQ-OV28 . OUTLINE : This multicenter study . Patients stratify accord prior therapy disease . Questionnaires design complete patient without help . Patients complete EORTC QLQ-C30 , QLQ-OV28 , debrief questionnaire regard time completion patient 's reaction quality life questionnaires accord one follow schedule : Group 1 : Patients complete questionnaire prior start first course chemotherapy , first day third course chemotherapy . Group 2 : Patients complete questionnaire 1 8 week follow completion 6th course chemotherapy prior anticancer therapy . Group 3 : Patients complete questionnaire routine follow-up clinic visit home within 3 day clinic visit . Group 4 : Patients complete questionnaire prior first course chemotherapy first day 3rd course chemotherapy prior administration OR first clinical review follow 2 course chemotherapy OR 2 month later patient receive continuous weekly chemotherapy . If unable complete write questionnaire due physical limitation illiteracy , express strong preference oral administration , patient Groups 1 , 2 , 4 may complete questionnaire orally instead . PROJECTED ACCRUAL : A minimum 280 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ovarian epithelial carcinoma No prior participation study member different group Group 1 : Prior surgery require Scheduled first line chemotherapy No chemotherapy prior surgery Group 2 : Prior surgery require Completion 6 course first line platinumbased chemotherapy require within 8 week prior study Group 3 : Must achieve complete response first line therapy At least 3 month since therapy cancer Prior surgery require Prior chemotherapy allow Prior radiotherapy allow Group 4 : Must recurrent disease Scheduled chemotherapy Prior surgery require Prior chemotherapy allow Prior radiotherapy allow PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No concurrent malignancies except basal cell carcinoma skin No mental disease language barrier would prevent compliance No concurrent participation quality life study might interfere study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>